Lundbeck to acquire Prexton Therapeutics in $1.1bn deal to expand Parkinson’s Disease treatment portfolio

Lundbeck, a leading Danish pharmaceutical company, has announced its acquisition of Prexton Therapeutics, a Swiss firm specializing in the development of drugs for Parkinson's disease, ... Read More